COMP <GO>
AKBA vs ADCT // GROSS PROFIT MARGIN
Akebia Therapeutics Inc. (NASDAQ) VS. ADC Therapeutics SA (NYSE) • 15-METRIC TALLY: AKBA 5
— ADCT 3
▲ GROSS PROFIT MARGIN LEADER: ADCT
LAST: $0.71 (+0.27%) • MKT CAP: $196.3M
gross-margins
83.30%
LAST: $1.54 (+0.65%) • MKT CAP: $196.6M
gross-margins
92.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AKBA VS. ADCT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AKBA | ADCT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 83.30% | 92.90% | -9.60 | ADCT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | -35.00% | +120.00 | AKBA | /roic <GO> |
| EV/EBITDA & P/E Valuation | 4.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 9.90% | -60.00% | +69.90 | AKBA | /operating-margins <GO> |
| Net Profit Margin | -2.20% | -60.00% | +57.80 | AKBA | /net-margins <GO> |
| Revenue Growth (YoY) | 47.50% | 14.90% | +32.60 | AKBA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 5/9 | +2.00 | AKBA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.2 | 54.3 | -9.10 | ADCT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $196.3M | $196.6M | -$306.2K | ADCT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AKBA REV | ADCT REV | AKBA GROSS % | ADCT GROSS % | AKBA FCF | ADCT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $236.2M | $81.4M | 83.3% | 92.9% | $67.7M | -$141.4M |
| FY 2024 | $160.2M | $70.8M | 60.6% | 91.6% | -$40.7M | -$124.7M |
| FY 2023 | $194.6M | $69.1M | — | — | -$23.4M | -$118.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AKBA // BETA —
ADCT // BETA —